Variables | KRAS Wild-type n = 34 (68.0%) | KRAS Mutated n = 16 (32.0%) | Univariate P* |
---|---|---|---|
Clinical factors | |||
 Sex | |||
  Male/female | 19/15 | 10/6 | 0.763 |
 Age (years) | 69 (32 − 81) | 69 (47 − 84) | 0.303 |
 CEA (ng/mL) | 2.8 (0.4 − 133.1) | 4.0 (1.0 − 116.6) | 0.163 |
 CA19-9 (IU/mL) | 65.0 (0.8 − 3055.0) | 38.7 (0.7 − 766.0) | 0.593 |
 Tumor size (cm) | |||
  Radiographical | 4.0 (1.0 − 13.0) | 3.0 (1.0 − 14.0) | 0.493 |
Treatment factors | |||
 R0 resection, n (%) | 33 (97.1) | 15 (93.8) | 0.542 |
 Minor hepatectomy, n (%) | 4 (11.8) | 2 (12.5) | 1.000 |
 Morbidity | |||
  C-D class III/IV, n (%) | 9 (26.5) | 3 (18.8) | 0.728 |
 Preoperative chemotherapy | |||
  Present, n (%) | 0 | 0 | 0 |
 Adjuvant chemotherapy | |||
  Present, n (%) | 22 (64.7) | 8 (50.0) | 0.366 |
Pathological factors | |||
 Tumor differentiation | |||
  Well/moderate, n (%) | 31 (91.2) | 12 (75.0) | 0.190 |
  Poor, n (%) | 3 (8.8) | 4 (25.0) |  |
 GLUT-1 expression | 1.0 (0.0 − 4.0) | 4.0 (2.0 − 4.0) | < 0.001 |
 Vascular invasion | |||
  Present, n (%) | 22 (64.7) | 12 (75.0) | 0.533 |
 Bile duct invasion | |||
  Present, n (%) | 16 (47.1) | 8 (50.0) | 1.000 |
 Lymph node metastasis | |||
  Present, n (%) | 10 (29.4) | 5 (31.3) | 1.000 |
 Tumor number | |||
  Multiple, n (%) | 6 (17.6) | 9 (56.3) | 0.008 |
 Tumor size (cm) | |||
  Pathological | 3.6 (1.0 − 13.0) | 3.4 (1.0 − 14.0) | 0.532 |
 AJCC stage | |||
  IV, n (%) | 16 (47.1) | 9 (56.3) | 0.762 |